CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 222 enrolled
Drug / intervention
XP13512 (GSK1838262) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00298623
NCT00298623Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.

XenoPort, Inc.·interventional·Posted Mar 2, 2006·Updated May 14, 2013

In Brief

A Phase 3 clinical trial evaluating XP13512 (GSK1838262) and placebo for Restless Legs Syndrome. Completed, enrolled 222 participants.

Detailed Summary

The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs Syndrome
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2, 2006
Enrollment StartMar 1, 2006
Primary CompletionFeb 1, 2007
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 20.3 years ago

Interventions

XP13512 (GSK1838262)drug

placeboother